Genmab A (GMAB) Liabilities and Shareholders Equity (2019 - 2026)

Genmab A's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $12.4 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 87.91% year-over-year to $12.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.7 billion (up 197.95% YoY) and the FY2025 annual result came in at $12.9 billion, up 100.7% from the prior year.
• Liabilities and Shareholders Equity was $12.4 billion for Q1 2026 at Genmab A, down from $12.9 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $12.9 billion in Q4 2025 and bottomed at $5.2 billion in Q4 2023.
• A 4-year average of $8.1 billion and a median of $6.6 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity advanced 22.59% — and 2025, when it surged 100.7%.
• Genmab A's Liabilities and Shareholders Equity stood at $5.2 billion in 2023, then gained by 22.59% to $6.4 billion in 2024, then soared by 100.7% to $12.9 billion in 2025, then declined by 3.86% to $12.4 billion in 2026.
• Business Quant data shows GMAB's Liabilities and Shareholders Equity at $12.4 billion in Q1 2026, $12.9 billion in Q4 2025, and $7.0 billion in Q3 2025.